Abstract:The escalation in opioid pain relief (OPR) medications, heroin and fentanyl, has led to an increased use during pregnancy and a public health crisis. Methamphetamine use in women of childbearing age has now eclipsed the use of cocaine and other stimulants globally. Recent reports have shown increases in methamphetamine are selective to opioid use, particularly in rural regions in the US. This report compares the extent of our knowledge of the perinatal outcomes of OPRs, heroin, fentanyl, two long-acting substances used in the treatment of opioid use disorders (buprenorphine and methadone), and methamphetamine. The methodological limitations of the current research are examined, and two important initiatives that will address these limitations are reviewed. Current knowledge of the perinatal effects of short-acting opioids, OPRs, heroin, and fentanyl, is scarce. Most of what we know about the perinatal effects of opioids comes from research on the long-acting opioid agonist drugs used in the treatment of OUDs, methadone and buprenorphine. Both have better perinatal outcomes for the mother and newborn than heroin, but the uptake of these opioid substitution programs is poor (<50%). Current research on perinatal outcomes of methamphetamine is limited to retrospective epidemiological studies, chart reviews, one study from a treatment center in Hawaii, and the US and NZ cross-cultural infant Development, Environment And Lifestyle IDEAL studies. Characteristics of pregnant individuals in both opioid and MA studies were associated with poor maternal health, higher rates of mental illness, trauma, and poverty. Infant outcomes that differed between opioid and MA exposure included variations in neurobehavior at birth which could complicate the diagnosis and treatment of neonatal opioid withdrawal (NOWs). Given the complexity of OUDs in pregnant individuals and the increasing co-use of these opioids with MA, large studies are needed. These studies need to address the many confounders to perinatal outcomes and employ neurodevelopmental markers at birth that can help predict long-term neurodevelopmental outcomes. Two US initiatives that can provide critical research and treatment answers to this public health crisis are the US Environmental influences on Child Health Outcomes (ECHO) program and the Medication for Opioid Use Disorder During Pregnancy Network (MAT-LINK).

Maternal exposure to buprenorphine, but not methadone, during pregnancy reduces social play behavior across two generations of offspring

Molecular and Long-Term Behavioral Consequences of Neonatal Opioid Exposure and Withdrawal in Mice.

The effects of buprenorphine and morphine during pregnancy: Impact of exposure length on maternal brain, behavior, and offspring neurodevelopment

Prenatal methadone exposure and child developmental outcomes in 2-year-old children

Maternal care behavior and physiology moderate offspring outcomes following gestational exposure to opioids

Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model

Peripartum buprenorphine and oxycodone exposure impair maternal behavior and increase neuroinflammation in the brains of new mother rats

Prenatal buprenorphine exposure decreases neurogenesis in rats

Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population-based study

Verbal and nonverbal memory in school-aged children born to opioid-dependent mothers

Paternal morphine exposure in rats reduces social play in adolescent male progeny without affecting drug-taking behavior in juvenile males or female offspring

Prenatal Opioid Use Disorder Treatment—the Importance of Shared Decision-Making

Prenatal heroin exposure alters brain morphology and connectivity in adolescent mice

Prenatal buprenorphine/naloxone exposure and neonatal neurobehavioral functioning: A preliminary report

Parental Exposure to Morphine Before Conception Decreases Morphine and Cocaine‐Induced Locomotor Sensitization in Male Offspring

Opioid exposure in gestation, postnatal adversity, and preschool-age cognitive functioning

Effects of prenatal opioid exposure on infant sympathetic and parasympathetic nervous system activity

Buprenorphine and methadone differentially alter early brain development in human cortical organoids

Neurobehavioral Characterization of Perinatal Oxycodone-Exposed Offspring in Early Adolescence

Buprenorphine Induces Human Fetal Membrane Sterile Inflammation

Opioid, methamphetamine, and polysubstance use: perinatal outcomes for the mother and infant